| Symbol | ANNX |
|---|---|
| Name | ANNEXON, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1400 SIERRA POINT PARKWAY, BLDG C,SUITE 200, BRISBANE, California, 94005, United States |
| Telephone | +1 650 822-5500 |
| Fax | — |
| — | |
| Website | https://www.annexonbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexons product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. Additional info from NASDAQ: |
New Form PRE 14A - Annexon, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001140361-26-015123 <b>Size:</b> 5 MB
Read moreCarson William H. 🟢 acquired 8.0K shares of Annexon, Inc. (ANNX) at $6.20 Transaction Date: Apr 10, 2026 | Filing ID: 000003
Read moreAnnexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Read moreNew Form SCHEDULE 13G/A - Annexon, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000619 <b>Size:</b> 7 KB
Read moreAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Read moreCarson William H. 🟢 acquired 8.0K shares of Annexon, Inc. (ANNX) at $5.67 Transaction Date: Mar 10, 2026 | Filing ID: 000002
Read moreDananberg Jamie 🔴 sold 5.8K shares of Annexon, Inc. (ANNX) at $5.43 Transaction Date: Mar 02, 2026 | Filing ID: 000003
Read moreOverdorf Michael 🔴 sold 4.3K shares of Annexon, Inc. (ANNX) at $5.42 Transaction Date: Mar 02, 2026 | Filing ID: 000003
Read moreYednock Ted 🔴 sold 5.6K shares of Annexon, Inc. (ANNX) at $5.42 Transaction Date: Mar 02, 2026 | Filing ID: 000003
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07020819 | An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as A… | Phase3 | Guillain-Barre Syndrome | Recruiting | 2025-09-12 | 2028-06-30 | ClinicalTrials.gov |
| NCT06510816 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections … | Phase3 | Geographic Atrophy | Active_Not_Recruiting | 2024-07-30 | 2027-10-31 | ClinicalTrials.gov |
| NCT05521269 | Dose Study of ANX1502 in Healthy Volunteers | Phase1 | Healthy | Completed | 2022-06-27 | 2024-11-19 | ClinicalTrials.gov |
| NCT05288881 | Single Ascending Dose Study of ANX105 | Phase1 | Healthy | Completed | 2022-02-28 | 2023-06-19 | ClinicalTrials.gov |
| NCT04691570 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Partic… | Phase2 | Warm Autoimmune Hemolytic Anemia (wAIHA) | Completed | 2021-11-10 | 2023-01-17 | ClinicalTrials.gov |
| NCT04656561 | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX… | Phase2 | Geographic Atrophy | Completed | 2021-02-26 | 2023-09-13 | ClinicalTrials.gov |
| NCT04701164 | Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome | Phase3 | Guillain-Barre Syndrome | Completed | 2020-12-17 | 2024-04-20 | ClinicalTrials.gov |
| NCT04535752 | A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Voluntee… | Phase1 | Safety and Tolerability in Healthy Volunteers | Completed | 2020-10-30 | 2021-06-26 | ClinicalTrials.gov |
| NCT04514367 | An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntin… | Phase2 | Huntington Disease | Completed | 2020-08-17 | 2022-01-28 | ClinicalTrials.gov |
| NCT04188015 | Study of ANX007 in Participants With Primary Open-angle Glaucoma | Phase1 | Open Angle Glaucoma | Completed | 2018-07-25 | 2019-06-03 | ClinicalTrials.gov |
| NCT03488550 | Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma | Phase1 | Open-angle Glaucoma | Completed | 2018-03-23 | 2018-08-03 | ClinicalTrials.gov |
| NCT03010046 | Single Dose Study of ANX005 in Healthy Volunteers | Phase1 | Safety and Tolerability in Healthy Volunteers | Terminated | 2016-12-01 | 2018-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Tanruprubart | DRUG | Phase PHASE3 | Guillain-Barre Syndrome | RECRUITING | NCT07020819 |
| Sham Administration | OTHER | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| Vonaprument | DRUG | Phase PHASE3 | Geographic Atrophy | ACTIVE_NOT_RECRUITING | NCT06510816 |
| ANX1502 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX105 | BIOLOGICAL | Phase PHASE1 | Healthy | COMPLETED | NCT05288881 |
| Sham comparator | OTHER | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| Placebo | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05521269 |
| ANX009 | BIOLOGICAL | Phase PHASE1 | Lupus Nephritis | COMPLETED | NCT05780515 |
| Sham Procedure | OTHER | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 5.0mg ANX007 | BIOLOGICAL | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| 2.5mg ANX007 | BIOLOGICAL | Phase PHASE1 | Open Angle Glaucoma | COMPLETED | NCT04188015 |
| Intravenous immunoglobulin | DRUG | Phase PHASE1 | Guillain-Barré Syndrome | COMPLETED | NCT04035135 |
| ANX007 | DRUG | Phase PHASE2 | Geographic Atrophy | COMPLETED | NCT04656561 |
| Placebos | DRUG | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| IVIg | DRUG | Phase PHASE1 | Safety and Tolerability in Healthy Volunteers | TERMINATED | NCT03010046 |
| ANX005 | DRUG | Phase PHASE3 | Guillain-Barre Syndrome | COMPLETED | NCT04701164 |